7 Cancer Drug Stocks to Know Right Now

BOSTON ( TheStreet) -- The ides of March are upon us, when thoughts turn to spring training, daffodils, March Madness . . . and cancer drug stocks.

The American Society of Clinical Oncology annual meeting kicks off in the first week in June. Seems far off but it's not, especially since savvy investors know that making money on the "ASCO trade" means getting in early as cancer drug stocks typically trade up into the closely watched medical meeting.

To help with your ASCO prep, capsule summaries of seven stocks expected to present significant cancer drug research at this year's ASCO meeting are presented on the following pages. Lots more will be said about these and other cancer drug stocks as we get closer to the meeting. Circle May 16 on your calendar -- that's when ASCO will be posting research abstracts for the meeting on its Web site.

In no particular order, here are seven ASCO stocks every biotech investor should have on their radar screens, beginning with Celldex Therapeutics ( CLDX):

If you liked this article you might like

Insider Trading Alert - SUMR, CVO And ARQL Traded By Insiders

Insider Trading Alert - ARQL, MTSC And PFNX Traded By Insiders

Insider Trading Alert - SAVE, ARQL And THST Traded By Insiders

Insider Trading Alert - ORM, OLBK And ARQL Traded By Insiders

Insider Trading Alert - TIPT, RDNT And ARQL Traded By Insiders